دورية أكاديمية
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
| العنوان: | Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized? |
|---|---|
| المؤلفون: | Scheen, André |
| المصدر: | Expert Review of Clinical Pharmacology, 16 (11), 1053-1062 (2024) |
| بيانات النشر: | Taylor & Francis |
| سنة النشر: | 2024 |
| المجموعة: | University of Liège: ORBi (Open Repository and Bibliography) |
| مصطلحات موضوعية: | Hypoglycemic Agents, Cardiotonic Agents, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemic Agents/adverse effects, Diabetes Mellitus, Type 2/complications/drug therapy, Cardiotonic Agents/pharmacology, Heart Failure/drug therapy, Atherosclerosis/complications, Cardiovascular Diseases/prevention & control/complications, Glucagon-Like Peptide-1 Receptor/agonists, Atherosclerotic cardiovascular disease, GLP-1 receptor agonist, SGLT2 inhibitor, cardiovascular outcome trial, gliflozin, heart failure, real-world clinical practice, Human health sciences, Endocrinology, metabolism & nutrition, Pharmacy, pharmacology & toxicology, Cardiovascular & respiratory systems, Sciences de la santé humaine, Endocrinologie, métabolisme & nutrition, Pharmacie, pharmacologie & toxicologie |
| الوصف: | peer reviewed ; INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective, yet not fully reached in clinical practice. AREAS COVERED: Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven their efficacy in reducing major cardiovascular events in high-risk patients with T2DM and SGLT2is in reducing hospitalization for HF in placebo-controlled randomized trials. However, real-life studies worldwide revealed that only a minority of patients with T2DM receive either a GLP-1RA or an SGLT2i and surprisingly even less patients with established ASCVD or HF are treated with these cardioprotective antihyperglycemic agents. EXPERT OPINION: Bridging the gap between evidence-based cardiovascular protection with GLP-1RAs and SGLT2is and their underuse in daily clinical practice in patients with T2DM at high risk is crucial from a public health viewpoint. However, the task appears hazardous and the goal not attained considering the current failure. Education of specialists/primary care physicians and patients is critical. Multifaceted and coordinated interventions involving all actors (physicians, patients and broadly health-care system) must be implemented to stimulate the adoption of these cardioprotective antihyperglycemic medications as part of routine cardiovascular care among patients with T2DM. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1751-2433 1751-2441 |
| العلاقة: | urn:issn:1751-2433; urn:issn:1751-2441; https://orbi.uliege.be/handle/2268/312538Test; info:hdl:2268/312538; scopus-id:2-s2.0-85174726601; info:pmid:37919944 |
| DOI: | 10.1080/17512433.2023.2279193 |
| الإتاحة: | https://doi.org/10.1080/17512433.2023.2279193Test https://orbi.uliege.be/handle/2268/312538Test |
| حقوق: | restricted access ; http://purl.org/coar/access_right/c_16ecTest ; info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.924D5C08 |
| قاعدة البيانات: | BASE |
| تدمد: | 17512433 17512441 |
|---|---|
| DOI: | 10.1080/17512433.2023.2279193 |